MMDA-13 IMPACT OF BEVACIZUMAB DOSING ON EDEMA RESPONSE IN PATIENTS WITH RADIATION NECROSIS
Sydney Schultz, Jason Barreto, Carolyn Mead-Harvey, Ugur Sener · 2026
Read MMDA-13 IMPACT OF BEVACIZUMAB DOSING ON EDEMA RESPONSE IN PATIENTS WITH RADIATION NECROSIS by Sydney Schultz, Jason Barreto, Carolyn Mead-Harvey, Ugur Sener (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13448502.txt.
Description
Schultz and colleagues compared two doses of bevacizumab, a drug that blocks blood vessel growth signals, for treating radiation necrosis, which is tissue death and swelling after brain radiation. Their 2026 retrospective review covers adults treated between 2021 and 2024 for primary brain tumors or brain metastases. The best dose for shrinking the swelling around damaged tissue has been unclear.
Schultz reviewed 104 patients, split almost evenly between a lower and a higher dose, each given a median of four treatments. Brain swelling responses favored the higher dose, with large swelling reductions more common in that group. The authors add a caution: the higher-dose group contained far more primary brain tumor patients, while the lower-dose group held more lung and breast cancer cases. tumor mix may explain part of the difference and dosing guidance needs cleaner comparisons.
Catalog record
| CREATOR | Sydney Schultz, Jason Barreto, Carolyn Mead-Harvey, Ugur Sener |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |